Duos Technologies Expands Edge Data Centers with New Deployments

Published 11 hours agoDUOT

Duos Technologies Expands Edge Data Centers with New Deployments

Duos Technologies Group, Inc. (NASDAQ: DUOT) has unveiled an ambitious plan to enhance its Edge Data Center (EDC) operations, aiming to roll out 15 units by the end of 2025. The company accelerated this expansion in November 2024 with the deployment of three new EDCs in Texas, thanks to a collaboration with Accu-Tech. This rapid deployment aims to improve connectivity in underserved areas, giving Duos Technologies a faster route to market.

In support of this initiative, Duos Technologies has fortified its alliances with Accu-Tech and FiberLight. These partnerships are crucial for upgrading the company's infrastructure and network capabilities, which are essential for the effective deployment and management of the EDCs. On the financial front, Reuters reported a significant boost in Duos' revenue for the third quarter of 2024, where revenues soared by 112% to $3.24 million, nearly half of which came from recurring revenue streams.

Looking ahead, Duos Technologies aims to develop a high-density data center park in Texas in collaboration with the Pampa Energy Center. The goal is to launch the first 50MW data center by the end of 2025, utilizing a mix of natural gas, wind, and alternative fuels for energy. These strategic initiatives highlight Duos Technologies' commitment to growing its presence in edge computing and addressing the demands of data center services, especially in regions lacking robust connectivity.

Share this article

Twitter Facebook LinkedIn

Recent Articles

Acadia Pharmaceuticals Rises 35% After Patent Win for Nuplazid

Acadia Pharmaceuticals Rises 35% After Patent Win for Nuplazid

7 minutes agoACAD

Acadia Pharmaceuticals Inc. saw its stock soar following a crucial court ruling that upheld the validity of a key patent for its drug, Nuplazid. On December 13, 2023, the U.S. District Court for the District of Delaware ruled in favor of Acadia by affirming the '740 composition of matter patent for Nuplazid. This decision bars generic versions until 2030, securing Acadia's competitive edge with this Parkinson's disease medication. The company's stock surged approximately 35% after the announcement, signaling robust investor confidence in the drug's continued exclusivity. According to Zacks, the favorable court decision significantly enhanced Acadia's stock performance. The stock reached an intraday high of $25.00, with a closing price of $23.85, reflecting a change of $6.25 from the previous close. This increase aligns with investors' optimism about the sustained market presence of Nuplazid, which remains the first FDA-approved treatment for hallucinations and delusions associated with Parkinson's disease psychosis. Alongside the re-affirmed '740 patent, Acadia also holds other critical patents, including a method of use patent for the 10mg tablet that extends to 2037, and formulation patents for the 34mg capsule until 2038. This breadth of patent coverage positions Nuplazid firmly in the market, continuing to contribute significantly to the company's revenue stream. The legal success empowers Acadia with a fortified stance in the pharmaceutical market, reinforcing its financial prospects over the coming years.

Emergent BioSolutions Faces No Recent CEO Stock Purchases

Emergent BioSolutions Faces No Recent CEO Stock Purchases

37 minutes agoEBS

As of May 16, 2025, there have been no recent stock purchases by the CEO of Emergent BioSolutions. The latest insider activity occurred on March 12, 2025, when director Neal Franklin Fowler sold 35,000 shares at an average price of $5.83 each, amounting to roughly $204,050, according to investing.com. Emergent BioSolutions saw Joseph C. Papa taking the helm as its new President and CEO in February 2024, replacing Haywood Miller. Before Papa's appointment, the company encountered stock challenges, notably after the mishap with Johnson & Johnson's COVID-19 vaccine doses, a situation that contributed to stock volatility, as reported by Fox Business. With the absence of recent insider stock purchases by top executives, it remains crucial to look at factors like leadership changes, the company's financial health, and the overall market landscape when evaluating the company's trajectory.

Novo Nordisk CEO Steps Down Amid Competitive Pressures

Novo Nordisk CEO Steps Down Amid Competitive Pressures

52 minutes agoNVO

Novo Nordisk, the Danish pharmaceutical giant, has announced that CEO Lars Fruergaard Jørgensen will resign from his position. This decision comes as a mutual agreement between Jørgensen and the Novo Nordisk Foundation, aimed at addressing recent market challenges and shareholder concerns over dwindling company performance. Axios reported that the leadership change is seen as necessary to navigate the current turbulent market landscape. Novo Nordisk is currently grappling with heightened competition in the weight-loss drug sector, a situation compounded by the success of Eli Lilly's Zepbound. Financial strains have deepened, with the company's share price plummeting more than 50% since mid-2024. As a result, Novo Nordisk has revised its sales and profit forecasts downward, reflecting decreased market share and profitability. Financial pressures are also growing due to impending Medicare drug price negotiations in the U.S., which could impact the pricing of their popular drugs. Lars Fruergaard Jørgensen will remain temporarily to facilitate a smooth leadership transition. Meanwhile, the Novo Nordisk Foundation is strengthening its influence on the board, with chairman Lars Rebien Sørensen joining as an observer. Reuters has emphasized the significance of these changes as the company aims to regain its footing within the competitive pharmaceutical industry.

Bristol Myers Secures EU Approval for Opdivo in Lung Cancer Therapy

Bristol Myers Secures EU Approval for Opdivo in Lung Cancer Therapy

Bristol Myers Squibb has received approval from the European Commission to use its Opdivo (nivolumab) in combination with platinum-based chemotherapy for treating certain lung cancer patients. This treatment specifically targets adults with resectable non-small cell lung cancer (NSCLC) who exhibit a high risk of recurrence and have a tumor cell PD-L1 expression of 1% or greater. This approval stems from the promising results of the Phase 3 CheckMate -816 trial, where Opdivo and chemotherapy combination before surgery was shown to improve event-free survival and pathologic complete response when compared to chemotherapy alone. Notably, this marks the first time an immunotherapy-based option has been approved in the EU for neoadjuvant treatment of patients with resectable NSCLC, according to Nasdaq. Dr. Nicolas Girard, a thoracic oncology professor, highlighted the potential of this development to enhance treatment strategies for non-metastatic NSCLC and reduce cancer recurrence risks post-surgery. Following this milestone, Bristol Myers's stock saw a rise, trading at $45.81 USD, marking a 3.82% increase. This move reflects the company's ongoing commitment to providing advanced treatment options in the European market.